Internal Medicine, Nephrology · Los Angeles, CA
NPI
1932237013
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
0
Medicare group memberships
Hospitals
1
Hospital affiliations
4220 W 3rd St Ste 203
Los Angeles, CA, 90020
Phone (213) 480-3380
Medicare paid, 2024
$130K
1,683 services
Medicare patients, 2024
147
Average age 77
Drug cost, 2024
$735K
3,636 prescriptions
Company payments, 2025
$1,358
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Peter H Lee was code 99232 (hospital e&m - subsequent), 735 times for 71 patients. In total Peter H Lee billed 1,683 services in 19 codes, and Medicare paid $130K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 735 | 71 | $64.80 | $48K |
| 90960 ESRD Related Services (not dialysis) | Office | 141 | 19 | $293.57 | $41K |
| 99213 Office E&M - Established | Office | 113 | 40 | $76.27 | $8,619 |
| 90935 Hemodialysis | Facility | 112 | 18 | $58.21 | $6,520 |
| 99222 Hospital E&M - Initial | Facility | 94 | 71 | $107.24 | $10K |
| 99238 Hospital Discharge Management | Facility | 39 | 31 | $67.47 | $2,631 |
| 99204 Office E&M - New | Office | 29 | 29 | $142.63 | $4,136 |
| 99221 Hospital E&M - Initial | Facility | 12 | 11 | $67.55 | $811 |
By year: 2022 $106K for 1,911 services; 2023 $116K for 1,890 services; 2024 $130K for 1,683 services.
Medicare prescription drug claims, 2024
In 2024, the drug Peter H Lee prescribed most often to Medicare patients was Jardiance (Empagliflozin), with 189 prescriptions and refills. In total Peter H Lee wrote 3,636 Medicare prescriptions that cost $735K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | 189 | 214 | 37 | $125K |
| Tradjenta Linagliptin | 180 | 198 | 36 | $98K |
| Amlodipine Besylate Generic | 164 | 200 | 32 | $503 |
| Losartan Potassium Generic | 126 | 168 | 33 | $616 |
| Vascepa Icosapent Ethyl | 121 | 138 | 18 | $46K |
| Allopurinol Generic | 118 | 136 | 20 | $563 |
| Hydralazine Hcl Generic | 116 | 150 | 22 | $932 |
| Metoprolol Succinate Generic | 91 | 133 | 22 | $654 |
| Atorvastatin Calcium Generic | 84 | 104 | 11 | $536 |
| Kerendia Finerenone | 84 | 88 | 17 | $53K |
| Doxazosin Mesylate Generic | 80 | 110 | 15 | $853 |
| Procrit Epoetin Alfa | 75 | 91 | 13 | $74K |
| Furosemide Generic | 67 | 89 | 13 | $173 |
| Sevelamer Carbonate Generic | 62 | 73 | 16 | $10K |
| Tamsulosin Hcl Generic | 53 | 71 | Under 11 | $327 |
Brand drugs: 1,121 claims; generic drugs: 2,403 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Peter H Lee $1,358 ($1,358 in general payments such as food, travel and fees) from 10 companies. The largest payer was Akebia Therapeutics Inc with $317.
| Company | Payments | Amount |
|---|---|---|
| Akebia Therapeutics Inc AKBA | 4 | $317 |
| Ardelyx, Inc. ARDX | 7 | $293 |
| Boston Scientific Corporation BSX | 2 | $251 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $123 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $83.35 |
| Amgen Inc. AMGN | 2 | $59.96 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $50.26 |
| OPKO Pharmaceuticals, LLC | 1 | $23.18 |
| Novo Nordisk Inc NVO | 1 | $16.98 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.